APVO net incomeQ2 2026-$6.36M
APVO net income was -$6.36M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.20M a year earlier. For the full fiscal 2025 it was -$25.97M, compared with -$24.13M in fiscal 2024.
Aptevo Therapeutics Inc. (APVO) financials
For the twelve months ended Jun 30, 2026, Aptevo Therapeutics Inc. reported -$26.41M of net income.
- Net income, TTM
- -$26.41M
- Cash
- $9.80M
- Market cap
- $3.0M
FY2016FY2022
FY2016FY2025
FY2016FY2022
APVO revenue and earnings growth
APVO EPSQ2 2026-$5.31
APVO diluted EPS was -$5.31 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$87.27.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $3.11M | $12.29M | $4.31M | $32.42M | $23.07M | $14.66M | $9.98M |
| Cost of revenue | - | - | - | - | - | - | $19.93M | $11.21M | $5.01M | $12.47M |
| Gross profit | - | - | - | - | - | - | $12.50M | $11.85M | $9.65M | -$2.48M |
| Research and development | $14.54M | $14.38M | $17.11M | $17.88M | $18.99M | $17.85M | $24.76M | $35.38M | $29.02M | $29.12M |
| Selling, general and admin | $11.77M | $10.22M | $11.77M | $13.87M | $14.70M | $13.95M | $16.20M | $28.13M | $34.58M | $36.16M |
| Operating income | -$26.31M | -$24.60M | -$28.88M | -$28.64M | -$21.40M | -$27.49M | -$40.96M | -$51.66M | -$53.95M | -$138.77M |
| Pre-tax income | -$25.97M | -$24.13M | -$18.65M | $7.01M | -$29.41M | -$30.92M | -$43.06M | -$53.69M | -$55.89M | -$139.58M |
| Income tax | $0 | - | - | - | - | - | - | - | -$23.30M | -$19.69M |
| Net income | -$25.97M | -$24.13M | -$17.41M | $8.03M | -$28.46M | -$17.75M | -$40.45M | -$53.69M | $6.97M | -$112.42M |
| EPS, basic | -$87.27 | -$31460.23 | -$834058.80 | $24868.80 | -$96148.80 | -$82843.20 | -$219542.40 | -$530006.40 | $73180.80 | -$1230768.00 |
| EPS, diluted | -$87.27 | -$31460.23 | -$834058.80 | $24868.80 | -$96148.80 | -$82843.20 | -$219542.40 | -$530006.40 | $73180.80 | -$1230768.00 |
| Diluted shares | 315,535 | 767 | 20.875 | 322.154 | 295.957 | 214.073 | 184.156 | 101.461 | 96.208 | 91.266 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $21.62M | $8.71M | $16.90M | $22.64M | $45.04M | $39.98M | $12.45M | $30.64M | $7.09M | $10.08M |
| Short-term investments | - | - | - | - | - | - | - | - | $73.69M | $44.85M |
| Receivables | - | - | - | - | - | - | $7.02M | $5.22M | $2.14M | $307.0K |
| Inventory | - | - | - | - | - | - | $6.14M | $1.78M | $1.03M | $461.0K |
| Current assets | $23.08M | $10.66M | $19.07M | $27.45M | $52.57M | $47.26M | $30.00M | $48.69M | $95.08M | $71.41M |
| Total assets | $27.19M | $15.59M | $24.84M | $34.22M | $56.60M | $53.55M | $53.41M | $67.49M | $117.01M | $91.86M |
| Current liabilities | $6.05M | $6.21M | $7.22M | $8.71M | $34.76M | $14.54M | $38.24M | $17.61M | $18.51M | $19.54M |
| Short-term debt | - | - | - | $2.00M | $11.67M | $5.00M | $19.86M | - | $3.33M | - |
| Long-term debt | - | - | - | $1.46M | $3.71M | - | - | $19.28M | $15.73M | $18.38M |
| Total debt | - | - | $0 | $3.46M | $15.37M | $28.22M | - | $19.28M | $19.06M | $18.38M |
| Total liabilities | $9.81M | $10.84M | $12.62M | $16.24M | $55.38M | $36.95M | $41.57M | $37.09M | $34.97M | $41.29M |
| Shareholders' equity | $17.38M | $4.75M | $12.22M | $17.97M | $1.22M | $16.59M | $11.84M | $30.41M | $82.03M | $50.57M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.59M | -$23.79M | -$11.73M | -$21.02M | -$21.68M | -$29.32M | -$42.38M | -$51.42M | -$41.57M | -$36.86M |
| Capital expenditures | - | - | - | $29.0K | $713.0K | $88.0K | $153.0K | $976.0K | $1.40M | $2.51M |
| Free cash flow | - | - | - | -$21.05M | -$22.39M | -$29.41M | -$42.54M | -$52.40M | -$42.98M | -$39.37M |
| Investing cash flow | $0 | $0 | $0 | -$29.0K | -$713.0K | $28.03M | $4.10M | $72.80M | $29.46M | -$47.39M |
| Financing cash flow | $38.50M | $15.60M | $6.00M | -$2.62M | $26.16M | $23.87M | $20.15M | -$787.0K | $19.53M | $89.30M |
| Stock-based compensation | $96.0K | $1.07M | $2.19M | $1.80M | $1.64M | $1.25M | $1.60M | $2.14M | $4.88M | $3.81M |
| Depreciation and amortization | $240.0K | $352.0K | $567.0K | $901.0K | $1.14M | $1.41M | $2.23M | $2.39M | $3.13M | $3.36M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | -74.7% | 185.3% | -86.7% | 40.6% | 57.4% | 46.8% | -70.3% |
| Gross margin | - | - | - | - | - | - | 38.5% | 51.4% | 65.8% | -24.9% |
| Operating margin | - | - | - | -919.7% | -174.1% | -638.1% | -126.3% | -224.0% | -368.1% | -1389.8% |
| Net margin | - | - | - | 257.8% | -231.5% | -411.9% | -124.7% | -232.8% | 47.6% | -1125.8% |
| Free cash flow margin | - | - | - | -676.0% | -182.2% | -682.4% | -131.2% | -227.2% | -293.2% | -394.3% |
| Return on equity | -149.4% | -507.5% | -142.5% | 44.7% | -2340.2% | -107.0% | -341.6% | -176.6% | 8.5% | -222.3% |
| Return on assets | -95.5% | -154.8% | -70.1% | 23.5% | -50.3% | -33.1% | -75.7% | -79.5% | 6.0% | -122.4% |
| Current ratio | 3.82 | 1.72 | 2.64 | 3.15 | 1.51 | 3.25 | 0.78 | 2.76 | 5.14 | 3.65 |
| Debt to equity | - | - | 0.00 | 0.19 | 12.64 | 1.70 | - | 0.63 | 0.23 | 0.36 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.70M | $3.92M | $3.54M | $4.04M | $3.33M | $3.63M | $3.88M | $3.10M | $3.64M | $3.75M | $3.59M | $3.89M |
| Selling, general and admin | $2.75M | $2.91M | $2.46M | $3.57M | $2.90M | $2.85M | $2.50M | $2.11M | $2.38M | $3.23M | $2.79M | $2.67M |
| Operating income | -$6.44M | -$6.84M | -$6.00M | -$7.61M | -$6.23M | -$6.48M | -$6.38M | -$5.21M | -$6.02M | -$6.98M | -$6.38M | -$6.56M |
| Net income | -$6.36M | -$6.70M | -$5.81M | -$7.55M | -$6.20M | -$6.41M | -$6.31M | -$5.10M | -$5.88M | -$6.83M | -$5.90M | -$6.33M |
| EPS, basic | -$5.31 | -$6.41 | - | -$802.80 | -$151.29 | -$1581.81 | - | -$128829.60 | -$445305.60 | -$132555.60 | - | -$7977.60 |
| EPS, diluted | -$5.31 | -$6.41 | - | -$802.80 | -$151.29 | -$1581.81 | - | -$128829.60 | -$445305.60 | -$132555.60 | - | -$7977.60 |
| Diluted shares | 1.2M | 1.1M | - | 11,247.35 | 41,008 | 4,051 | - | 39.594 | 13.211 | 51.556 | - | 794.128 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.80M | $14.53M | $21.62M | $21.06M | $9.41M | $2.14M | $8.71M | $7.75M | $8.07M | $10.25M | $16.90M | $19.11M |
| Current assets | $10.80M | $15.98M | $23.08M | $22.65M | $11.08M | $3.61M | $10.66M | $10.01M | $9.58M | $12.07M | $19.07M | $21.13M |
| Total assets | $14.52M | $19.90M | $27.19M | $27.00M | $15.62M | $8.34M | $15.59M | $15.15M | $14.92M | $17.63M | $24.84M | $27.13M |
| Current liabilities | $5.19M | $4.76M | $6.05M | $5.61M | $4.89M | $5.39M | $6.21M | $5.88M | $5.42M | $6.30M | $7.22M | $6.84M |
| Total debt | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Total liabilities | $8.48M | $8.29M | $9.81M | $9.60M | $9.10M | $9.81M | $10.84M | $10.73M | $10.46M | $11.53M | $12.62M | $12.41M |
| Shareholders' equity | $6.04M | $11.61M | $17.38M | $17.39M | $6.52M | -$1.47M | $4.75M | $4.42M | $4.46M | $6.10M | $12.22M | $14.72M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.45M | -$7.96M | -$5.24M | -$6.69M | -$7.09M | -$6.58M | -$5.76M | -$5.22M | -$6.15M | -$6.65M | -$5.25M | -$6.24M |
| Investing cash flow | $0 | $0 | - | - | $0 | $0 | - | - | - | - | - | - |
| Financing cash flow | $726.0K | $871.0K | $5.79M | $18.34M | $14.36M | $0 | $6.72M | $4.91M | $3.97M | -$3.0K | $3.05M | $4.34M |
| Stock-based compensation | $58.0K | $57.0K | $2.0K | $77.0K | -$163.0K | $180.0K | -$72.0K | $149.0K | $273.0K | $719.0K | $358.0K | $455.0K |
| Depreciation and amortization | $32.0K | $35.0K | $81.0K | $49.0K | $49.0K | $61.0K | $71.0K | $84.0K | $91.0K | $106.0K | $116.0K | $123.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 2.08 | 3.36 | 3.82 | 4.03 | 2.27 | 0.67 | 1.72 | 1.70 | 1.77 | 1.92 | 2.64 | 3.09 |
| Debt to equity | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 |
Source: XBRL data Aptevo Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-14, first reported Aug 14, 2020; 1-for-44, first reported May 8, 2024; 1-for-360, first reported Mar 26, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
APVO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| APVO | - | - | -$26.41M | - | $3.0M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
APVO FAQ
4 questionsIs APVO profitable?
No. Aptevo Therapeutics Inc. reported a net loss of $26.41M for the twelve months ended Jun 30, 2026.How much cash and debt does APVO have?
Aptevo Therapeutics Inc. reported $9.80M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did APVO last report financial results?
The latest statements here come from Aptevo Therapeutics Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this APVO financial data come from?
Quantisnow builds these statements from the structured XBRL data Aptevo Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.